三维引导经会阴间质近距离放疗治疗宫颈癌的系统评价
该系统评价纳入19篇文献,评估经会阴间质近距离放疗(P-ISBT)联合三维图像计划治疗宫颈癌的局部控制与毒性。共672例患者接受治疗,其中392例可评估,60%为IIIB期或更高;局部控制率为79%(310/392),随访14–55个月,3–4级晚期胃肠、泌尿及阴道毒性合计12.1%。
要点
- P-ISBT联合三维计划治疗宫颈癌局部控制率达79%,其中60%为IIIB期或以上。
- 肿瘤总EQD2Gy剂量较低者局部控制较差。
- 3–4级晚期胃肠、泌尿及阴道毒性合计为12.1%。
核心结论
- 经会阴间质近距离放疗联合三维图像计划治疗宫颈癌局部控制率有前景,60%为IIIB期或更高仍达79%。
- 局部控制似乎与肿瘤剂量相关,毒性与其他三维图像计划近距离放疗系列相似。
研究设计与样本
- 遵循PRISMA指南的系统评价,检索Medline、EMBASE和Cochrane数据库,最终纳入19篇相关文献。
主要发现
- 共672例宫颈癌患者接受P-ISBT联合三维图像计划,其中392例可识别临床结局,60%为IIIB期或更高。
- 多数患者接受盆腔外照射45–50.4Gy后行P-ISBT推量,剂量范围28–48Gy EQD2Gy。
- 总局部控制率为79%(310/392),中位随访范围14–55个月,48%患者中位随访≥35个月。
- 肿瘤总EQD2Gy剂量较低者局部控制较差。
- 操作相关并发症罕见(7例感染和7例出血),3–4级晚期胃肠、泌尿及阴道毒性合计为12.1%。
关键数值与推荐
- 局部控制率79%(310/392),中位随访14–55个月,48%患者中位随访≥35个月。
- 外照射剂量45–50.4Gy,P-ISBT推量剂量28–48Gy EQD2Gy。
- 操作相关并发症:7例感染和7例出血;3–4级晚期胃肠、泌尿及阴道毒性合计12.1%。
临床怎么用
- P-ISBT联合三维计划可作为大体积晚期宫颈癌的有效且安全的治疗选择。
- 对于大体积晚期宫颈癌,P-ISBT可能是日益标准的腔内/间质(IC/IS)方法(如「Vienna」施源器)的合理替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate local control and toxicities of perineal-based interstitial brachytherapy (P-ISBT) in cervical cancers treated with three-dimensional (3D) image-based planning through a systematic review. The secondary objective of this review is to summarize the implant and dosimetric techniques in 3D P-ISBT. METHODS: Systematic review of the literature using the PRISMA guideline was conducted through a search of Medline, EMBASE and Cochrane databases. This search resulted in 19 relevant manuscripts. Selected studies evaluated the role of perineal ISBT in cervical tumours treated using 3D planning. Eleven of nineteen manuscripts contained sufficient information for LC and toxicity calculations. Data were extracted by at least two investigators. RESULTS: A total of 672 cervical cancer patients were treated with P-ISBT and planned with 3D image-based planning. Clinical outcomes could be identified for 392 patients and 60% were staged IIIB or higher. Most patients received 45-50.4Gy EBRT to the pelvis followed by a P-ISBT boost with a range of dose between 28 and 48Gy EQD2Gy. Overall LC was 79% (310/392) with a median follow-up ranging from 14 to 55months. Almost half of the patients (48%) had a median follow-up ≥35months. Patients treated to a lower tumour EQD2Gy total dose had inferior LC. Procedure-related complications were rare (7 infections and 7 episodes of bleeding) and limited. Combined late gastro-intestinal, genitourinary and vaginal grade 3 and 4 toxicity was 12.1%. CONCLUSION: Promising LC rates were found in patients with cervical cancers treated with perineal ISBT with 3D image-based planning. In this systematic review, 60% had stage IIIB disease or higher and yet a LC rate of 79% was found. LC seemed to correlate with the dose delivered to the tumour, while toxicity rates were similar to other cervical cancer series using 3D image-based brachytherapy. Perineal ISBT with 3D planning seems to be an effective and safe treatment for large advanced cervical tumours and may be a reasonable alternative to the increasingly more standard and modern intracavitary/interstitial (IC/IS) approaches such as the 'Vienna' applicator.
引用
- Mendez LC, Weiss Y, D'Souza D, et al. Three-dimensional-guided perineal-based interstitial brachytherapy in cervical cancer: A systematic review of technique, local control and toxicities. Radiother Oncol. 2017. PMID: 28351521. doi:10.1016/j.radonc.2017.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。